12
Participants
Start Date
November 30, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Testosterone undecanoate
Single-day dose as QD or BID for 3 of 5 crossover periods
Testosterone enanthate
Single-day dose for 2 of 5 crossover periods
dgd Research, Inc, San Antonio
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
OTHER
Clarus Therapeutics, Inc.
INDUSTRY